Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.

Levisay JP, Price MJ, Shaba W, Lee SS, Stinis CP, Miller L, Teirstein PS.

J Invasive Cardiol. 2010 May;22(5):216-9.

2.

Comparison of long-term outcomes following sirolimus-eluting stent vs paclitaxel-eluting stent implantation in patients with long calcified coronary lesions.

Hur SH, Cho YK, Nam CW, Kim H, Han SW, Kim YN, Park HJ, Park JS, Shin DG, Kim YJ, Shim BS, Yang TH, Kim DK, Kim DI, Kim DS, Kim KB.

Clin Cardiol. 2009 Nov;32(11):633-8. doi: 10.1002/clc.20591.

3.
4.

Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease.

Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ; Long-DES-II Study Investigators.

Circulation. 2006 Nov 14;114(20):2148-53. Epub 2006 Oct 23.

5.

The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.

Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW; Interventional Cardiologists of the Thoraxcenter.

JACC Cardiovasc Interv. 2010 Oct;3(10):1051-8. doi: 10.1016/j.jcin.2010.08.003.

6.

Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.

Kufner S, Byrne RA, de Waha A, Schulz S, Joner M, Laugwitz KL, Kastrati A; Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2, (ISAR-DESIRE 2) Investigators.

Cardiovasc Revasc Med. 2014 Mar;15(2):69-75. doi: 10.1016/j.carrev.2014.02.001. Epub 2014 Feb 15.

PMID:
24684757
7.

Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.

Chen J, Li JJ, Chen JL, Qiao SB, Xu B, Yang YJ, Gao RL, Qin XW, Yuan JQ, Yao M, Wu YJ, Liu HB, Dai J, You SJ.

Coron Artery Dis. 2008 Nov;19(7):507-11. doi: 10.1097/MCA.0b013e32830936d4.

PMID:
18923247
8.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators.

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

9.

Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.

Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G.

Circulation. 2009 Sep 15;120(11):964-72. doi: 10.1161/CIRCULATIONAHA.108.830372. Epub 2009 Aug 31. Retraction in: Circulation. 2010 Mar 2;121(8):e228.

10.

Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.

Ota H, Mahmoudi M, Kitabata H, Torguson R, Chen F, Satler LF, Suddath WO, Pichard AD, Waksman R.

Cardiovasc Revasc Med. 2015 Mar;16(2):84-9. doi: 10.1016/j.carrev.2015.01.004. Epub 2015 Jan 29.

PMID:
25870152
12.

Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.

Kim U, Kim DK, Seol SH, Yang TH, Kim DK, Kim DI, Kim DS, Lee SH, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Kim HS, Nam CW, Hur SH, Kim KB.

Clin Cardiol. 2010 Jun;33(6):340-4. doi: 10.1002/clc.20744.

13.

Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.

Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators.

J Am Coll Cardiol. 2010 Jun 15;55(24):2710-6. doi: 10.1016/j.jacc.2010.02.009. Epub 2010 Mar 11.

14.

The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.

Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G.

JACC Cardiovasc Interv. 2009 Jun;2(6):515-23. doi: 10.1016/j.jcin.2009.03.012.

15.

3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.

Holmes DR Jr, Teirstein PS, Satler L, Sketch MH Jr, Popma JJ, Mauri L, Wang HP, Schleckser PA, Cohen SA; SISR Investigators.

JACC Cardiovasc Interv. 2008 Aug;1(4):439-48. doi: 10.1016/j.jcin.2008.05.010.

16.

3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).

Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA; SPIRIT II Investigators.

JACC Cardiovasc Interv. 2009 Dec;2(12):1190-8. doi: 10.1016/j.jcin.2009.10.002.

17.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

18.

Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis.

Iofina E, Haager PK, Radke PW, Langenberg R, Blindt R, Ortlepp J, Kühl H, Hanrath P, Hoffmann R.

Catheter Cardiovasc Interv. 2005 Jan;64(1):28-34.

PMID:
15619307
19.

Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: results of long-term follow-up.

Freixa X, Almasood AS, Khan SQ, Wainstein R, Osherov A, Mackie K, Seidelin PH, Džavík V.

Catheter Cardiovasc Interv. 2012 Mar 1;79(4):559-65. doi: 10.1002/ccd.23031. Epub 2011 May 12.

PMID:
21567881
20.

Sirolimus- versus paclitaxel-eluting stents for coronary bifurcations intervention: a meta-analysis of five clinical trials.

Qian J, Chen Z, Ma J, Ge J.

Catheter Cardiovasc Interv. 2012 Oct 1;80(4):507-13. doi: 10.1002/ccd.23392. Epub 2011 Nov 1.

PMID:
22045690

Supplemental Content

Support Center